Asterand PLC Signs Global Agreement with Lundbeck


DETROIT, July 20, 2009 – Asterand plc (LSE: ATD), (“Asterand” or the “Company”), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, announces today that it has entered into a Global Framework Research Agreement with Lundbeck A/S, a leading international pharmaceutical company focused on the development of medications for central nervous system disorders. This agreement will allow scientists at Lundbeck’s global research locations to access Asterand’s XpressBANKTM of human tissue and clinical data and the PhaseZERO® drug discovery services platform to advance development of treatments for psychiatric and neurological disorders. Financial terms were not disclosed.

Martyn Coombs, CEO of Asterand commented:

“We are honoured that Lundbeck has chosen Asterand as a preferred human tissue solutions provider. As we seek avenues to create closer relationships with our key clients, this extended collaboration provides Asterand with the opportunity to assist Lundbeck in its quest to find treatments for difficult to treat diseases such as Alzheimer’s, Parkinson’s and Schizophrenia.”

Notes to Editors

About Asterand plc

About Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, Alzheimer’s and Parkinson’s diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the worlds leading pharmaceutical companies working with CNS disorders. In 2008, the company’s revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit

Facebook Comments